Abterra Biosciences, Inc.

San Diego, CA Doing business as Digital Proteomics

UEI
TYHDLNB65NJ1
CAGE
6G3U6
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
NAICS codes registered in SAM.gov
SAM.gov registration date
Physical address
11588 Sorrento Valley Rd # 16, San Diego, CA 92121, USA
Website
abterrabio.com
Founded
2009
Employees
1-10
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

About Abterra Biosciences, Inc.

Abterra Biosciences, Inc. is a company that specializes in antibody discovery and sequencing using next generation sequencing, mass spectrometry, and machine learning. Through federal contract awards, Abterra Biosciences has provided laboratory and testing services to the Department of Health and Human Services National Institutes of Health National Cancer Institute under a $15,000 purchase order. Additionally, the company was awarded a $540,608 firm fixed price definitive contract by the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases to deliver comprehensive reagents for immunophenotyping rabbit cell-mediated immunity, in support of research related to allergies and infectious diseases. This contract was designated as a total small business set aside.

Through federal grants, Abterra Biosciences has received funding to develop software for sequencing human antibody proteins from polyclonal immune responses, improve de novo peptide sequencing using machine learning, and enable targeted assembly of specificity determining regions and antibody frameworks. This software aims to identify antibody candidates without requiring a matched B-cell genetic antibody repertoire. The $3,905,928 project is funded by the National Institute of General Medical Sciences under the Biomedical Research and Research Training program. Additionally, the company was awarded $732,147 by the National Institute of General Medical Sciences to develop an intelligent in silico antibody library for therapeutic discovery, incorporating rules of natural antibody development to improve biophysical properties. Abterra Biosciences also received a $217,313 project grant from the National Institute of General Medical Sciences for immune repertoire sequencing error correction, analysis, and visualization.

Quick answers

What is Abterra Biosciences, Inc.'s UEI?

Abterra Biosciences, Inc.'s Unique Entity ID (UEI) in SAM.gov is TYHDLNB65NJ1.

What is Abterra Biosciences, Inc.'s CAGE code?

Abterra Biosciences, Inc.'s CAGE code is 6G3U6.

What is Abterra Biosciences, Inc.'s primary NAICS code?

Abterra Biosciences, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Where is Abterra Biosciences, Inc. located?

Abterra Biosciences, Inc.'s physical address in SAM.gov is 11588 Sorrento Valley Rd # 16, San Diego, CA 92121, USA.

Is Abterra Biosciences, Inc. registered in SAM.gov?

Yes. Abterra Biosciences, Inc.'s SAM.gov registration is active through September 4, 2027.

What is Abterra Biosciences, Inc.'s most recent federal award?

Abterra Biosciences, Inc.'s most recent federal grant award is A platform for serum antibody repertoire analysis for autoimmune disease diagnosis - systemic lupus erythematosus… (R43AI197772), from National Institute of Allergy and Infectious Diseases, on August 17, 2026.

On GovTribe

See Abterra Biosciences, Inc.'s full federal record

  • Federal contract awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors